These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25707537)

  • 1. Computational cell fate modelling for discovery of rewiring in apoptotic network for enhanced cancer drug sensitivity.
    Mishra SK; Bhowmick SS; Chua H; Zhang F; Zheng J
    BMC Syst Biol; 2015; 9 Suppl 1(Suppl 1):S4. PubMed ID: 25707537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment.
    Rodriguez-Nieto S; Zhivotovsky B
    Curr Pharm Des; 2006; 12(34):4411-25. PubMed ID: 17168751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mathematical modeling and computational prediction of cancer drug resistance.
    Sun X; Hu B
    Brief Bioinform; 2018 Nov; 19(6):1382-1399. PubMed ID: 28981626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feedback regulation in cell signalling: Lessons for cancer therapeutics.
    Nguyen LK; Kholodenko BN
    Semin Cell Dev Biol; 2016 Feb; 50():85-94. PubMed ID: 26481970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for multiple signalling inhibition.
    Tortora G; Bianco R; Daniele G
    J Chemother; 2004 Nov; 16 Suppl 4():41-3. PubMed ID: 15688608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms for tumour resistance to chemotherapy.
    Pan ST; Li ZL; He ZX; Qiu JX; Zhou SF
    Clin Exp Pharmacol Physiol; 2016 Aug; 43(8):723-37. PubMed ID: 27097837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in gene expression profiles and carcinogenesis pathways involved in cisplatin resistance of four types of cancer.
    Yang Y; Li H; Hou S; Hu B; Liu J; Wang J
    Oncol Rep; 2013 Aug; 30(2):596-614. PubMed ID: 23733047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer.
    Shin SY; Müller AK; Verma N; Lev S; Nguyen LK
    PLoS Comput Biol; 2018 Jun; 14(6):e1006192. PubMed ID: 29920512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational design, chemical synthesis, and biological evaluation of a novel ERK inhibitor (BL-EI001) with apoptosis-inducing mechanisms in breast cancer.
    Liu B; Fu L; Zhang C; Zhang L; Zhang Y; Ouyang L; He G; Huang J
    Oncotarget; 2015 Mar; 6(9):6762-75. PubMed ID: 25742792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells.
    Alimbetov D; Askarova S; Umbayev B; Davis T; Kipling D
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29882812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.
    Carrella D; Manni I; Tumaini B; Dattilo R; Papaccio F; Mutarelli M; Sirci F; Amoreo CA; Mottolese M; Iezzi M; Ciolli L; Aria V; Bosotti R; Isacchi A; Loreni F; Bardelli A; Avvedimento VE; di Bernardo D; Cardone L
    Oncotarget; 2016 Sep; 7(37):58743-58758. PubMed ID: 27542212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A hybrid computational model for the effects of maspin on cancer cell dynamics.
    Al-Mamun MA; Brown LJ; Hossain MA; Fall C; Wagstaff L; Bass R
    J Theor Biol; 2013 Nov; 337():150-60. PubMed ID: 23988797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    Gohr K; Hamacher A; Engelke LH; Kassack MU
    BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat shock protein 27 is a potential indicator for response to YangZheng XiaoJi and chemotherapy agents in cancer cells.
    Owen S; Zhao H; Dart A; Wang Y; Ruge F; Gao Y; Wei C; Wu Y; Jiang WG
    Int J Oncol; 2016 Nov; 49(5):1839-1847. PubMed ID: 27600495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoresistance of Lung and Breast Cancer Cells Growing Under Prolonged Periods of Serum Starvation.
    Yakisich JS; Venkatadri R; Azad N; Iyer AKV
    J Cell Physiol; 2017 Aug; 232(8):2033-2043. PubMed ID: 27504932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Developmental Pathways: The Achilles Heel of Cancer?
    Dempke WCM; Fenchel K; Uciechowski P; Chevassut T
    Oncology; 2017; 93(4):213-223. PubMed ID: 28738360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Killing time for cancer cells.
    Klein S; McCormick F; Levitzki A
    Nat Rev Cancer; 2005 Jul; 5(7):573-80. PubMed ID: 15965492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling of the cancer cell cycle as a tool for rational drug development: A systems pharmacology approach to cyclotherapy.
    Jackson RC; Di Veroli GY; Koh SB; Goldlust I; Richards FM; Jodrell DI
    PLoS Comput Biol; 2017 May; 13(5):e1005529. PubMed ID: 28467408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.